Repairon publishes BioVAT-HF trial results

Repairon, a German biotechnology company, announced the publication of positive Phase 1-2 clinical trial results for its engineered human heart muscle tissue in the The New England Journal of Medicine. The BioVAT-HF trial demonstrated that the heart muscle patches, derived from human induced pluripotent stem cells, can restore heart muscle function in patients with advanced heart failure, leading to improved health and quality of life. Key findings include increased heart wall thickness, improved left ventricular ejection fraction, and enhanced quality of life. While some adverse events occurred, they were largely unrelated to the BioVAT. Wolfram-Hubertus Zimmermann, the principal author and researcher whose work founded Repairon, and Lothar Germeroth, Repairon's CEO, both expressed optimism about the therapy's potential to address the high medical need in advanced heart failure, a condition affecting millions globally.